Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients

Myelodysplastic syndromes

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Lancet Haematol

Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A, Hellström-Lindberg E

doi: 10.1016/S2352-3026(24)00350-8

Myelodysplastic syndromes

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Adv Ther

Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Pozharskaya V, Rose S, Keeperman K, Lai Y, Kalsekar S, Aggarwal B, Miteva D, Valcárcel D, Fenaux P, Shortt J, Della Porta MG, Platzbecker U

doi: 10.1007/s12325-025-03208-5

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Myelodysplastic syndromes

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms

Br J Haematol

Maeda T, Matsuda A, Kanda J, Kawabata H, Ishikawa T, Tohyama K, Kitanaka A, Araseki K, Shimbo K, Hata T, Suzuki T, Kayano H, Usuki K, Shindo-Ueda M, Arima N, Nohgawa M, Ohta A, Chiba S, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A, Mitani K, Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

doi: 10.1111/bjh.20097

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

Skin Cancer

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Eur J Cancer

van der Kooij MK, Kapiteijn E, Rutkowski P, Baurain JF, de Koning L, Speetjens FM, Bartoszek P, Rogala P, Cornélis F, Dudzisz-Śledź M, Rodrigues M, Piperno-Neumann S

doi: 10.1016/j.ejca.2025.115634

Myelodysplastic syndromes

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Br J Haematol

Papantoniou M, Stergiou I, Giannouli S, Bountziouka C, Kokotis P

doi: 10.1111/bjh.19901

Non-Malignant Blood Disorders

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Br J Haematol

Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, De Stefano V, Gaidano G, Palandri F, Auteri G, Rossi E, Patriarca A, Innao V, Marchesini G, Ballerini M, Rossetti MC, Mosini G, Sciancalepore P, Agnelli Giacchello J, Musto P, Rivolti E, Soverini G, Borchiellini A, Clissa C, Pane F, Galimberti S, Pavone V, Poloni A, Buccisano F, Musso M, Fazi P, Paoloni F, Gorreo Renzulli L, Zaja F

doi: 10.1111/bjh.70069

Leukemia

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Leuk Lymphoma

Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K

doi: 10.1080/10428194.2025.2535693

Related content

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group